Sugi Predict

Sugi Predict / Compounds / SCHEMBL18338474

SCHEMBL18338474

SCHEMBL18338474

COc1ccc2ccnn2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 2/20 0.45
▸ DRD4 P21917 2/20 0.45
▸ DRD3 P35462 2/20 0.45
▸ DRD1 P21728 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ CLK4 Q9HAZ1 2/20 0.38
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ KDR P35968 5/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25416514 0.85 KDR (0.47) CLK4RAB9AKDRNPC1FLT1
SCHEMBL25421011 0.79 DRD2 (0.45) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL30977339 0.79 DRD2 (0.38) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL24567001 0.79 DRD2 (0.54) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL25416819 0.77 BRD4 (0.52) CLK4RAB9AMAPTKMT2AKDR
SCHEMBL31024092 0.77 BRD4 (0.52) CLK4RAB9AMAPTKMT2AKDR
SCHEMBL30977412 0.76 RXRA (0.36) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL22747519 0.73 DRD2 (0.37) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL12708991 0.72 SLC6A2 (0.40) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL31416822 0.72 MEN1 (0.42) DRD2DRD4DRD3DRD1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-4619402-A1 GPR17 MODULATORS AND USES THEREOF Myrobalan Therapeutics, Inc. (US) 2025-09-24 — — EP disclosed
CN-119613397-A N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors 迈巴制药(南京)有限公司 2025-03-14 — — CN disclosed
WO-2024104462-A1 GPR17 MODULATORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2024-05-23 — — WO disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
US-20220340592-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2022-10-27 — — US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 — — US disclosed
WO-2022140527-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
US-11352369-B2 Pyridine and pyrimidine derivatives ASTRAZENECA AB (SE) 2022-06-07 — — US disclosed
EP-3313838-B1 POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS ASTRAZENECA AB (SE) 2019-04-03 — — EP disclosed
US-20180093998-A1 CHEMICAL COMPOUNDS ASTRAZENECA PHARMACEUTICALS LP 2018-04-05 — — US disclosed
US-20180093998-A1 CHEMICAL COMPOUNDS ASTRAZENECA PHARMACEUTICALS LP 2018-04-05 — — US disclosed
US-20180093998-A1 CHEMICAL COMPOUNDS ASTRAZENECA PHARMACEUTICALS LP 2018-04-05 — — US disclosed
US-9845331-B2 Chemical compounds ASTRAZENECA AB (SE) 2017-12-19 — — US disclosed
US-9845331-B2 Chemical compounds ASTRAZENECA AB (SE) 2017-12-19 — — US disclosed
US-9845331-B2 Chemical compounds ASTRAZENECA AB (SE) 2017-12-19 — — US disclosed
WO-2017001354-A1 POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS ASTRAZENECA AB (SE) 2017-01-05 — — WO disclosed
US-20160376287-A1 Chemical Compounds ASTRAZENECA AB (SE) 2016-12-29 — — US disclosed
US-20160376287-A1 Chemical Compounds ASTRAZENECA AB (SE) 2016-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340592-A1 CHEMICAL COMPOUNDS CDK9, BCL9, BCL9L DRD2 1173/4885DRD4 1917/4885DRD3 2343/4885
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP DRD2 955/4885DRD4 1861/4885DRD3 1018/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH DRD2 497/4885DRD4 1036/4885DRD3 295/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP DRD2 955/4885DRD4 1861/4885DRD3 1018/4885
US-20160376287-A1 Chemical Compounds CDK9, BCL9, BCL9L DRD2 1173/4885DRD4 1917/4885DRD3 2343/4885
US-20180093998-A1 CHEMICAL COMPOUNDS CDK9, BCL9, BCL9L DRD2 1173/4885DRD4 1917/4885DRD3 2343/4885
US-11352369-B2 Pyridine and pyrimidine derivatives CDK9, BCL9, CDK19 DRD2 1000/4885DRD4 1772/4885DRD3 2218/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP DRD2 955/4885DRD4 1861/4885DRD3 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.